Clinical profile of severe asthmatics receiving biological treatment: see behind the scenes

Abstract

The clinical phenotyping of severe asthma could improve treatment outcomes, quality of life, morbidity, and mortality of asthma patients. The growing availability of rich clinical data could provide opportunities to address a broad range of real-world questions regarding clinical phenotyping and effective therapeutic approaches of severe asthma. Accordingly, in this Letter to the Editor, we provide data relevant to constructing the clinical profile of a Greek severe asthma patient cohort who receive biological treatment.

Keywords:

• Asthma
• Greece
• mepolizumab
• omalizumab
• phenotype

Disclosure statement

No potential conflict of interest was reported by the author(s).